REFERENCES
- Naber KG, Dette GA, Kees F, Knothe H, Grobecker H. Pharmacokinetics, in
vitro activity, therapeutic efficacy, and clinical safety of aztreonam
vs. cefotaxime in the treatment of complicated urinary tract infections. J
Antimicrob Chemother 1986;17:517-527.
- Creasey WA, Platt TB, Frantz M, Sugerman AA. Pharmacokinetics of
aztreonam in elderly male volunteers. Br J Clin Pharmacol 1985;19:233-237.
- Meyers BR, Wilkinson P, Mendelson MH, et al. Pharmacokinetics
of aztreonam in healthy elderly and young adult volunteers. J Clin
Pharmacol 1993;33:470-474.
- Sattler FR, Schramm M, Swabb EA. Safety of aztreonam and SQ 26,992
in elderly patients with renal insufficiency. Rev Infect Dis 1985;7
(suppl 4):S622-S627.
- Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Ninth Edition. CLSI document M07-A9, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.
- National Committee for Clinical Laboratory Standards. Methods
for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically—Fifth
Edition. Approved Standard NCCLS Document M7-A5, Vol. 20, No. 2, NCCLS, Wayne,
PA, January 2000.
- Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard – Eleventh Edition CLSI document M02-A11, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.
- Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-third Informational Supplement, CLSI document M100-S23. CLSI document M100-S23, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2013.
- Deger F, Douchamps J, Freschi E, et al. Aztreonam in the treatment of serious gram-negative infections in the elderly. Int J Clin Pharmacol Ther and Toxicol 1988;26:22-26.
- Knockaert DC, Dejaeger E, Nestor L, et al. Aztreonam-flucloxacillin double beta-lactam treatment as empirical therapy of serious infections in very elderly patients. Age and Aging 1981;20:135-139.
- Roelandts F. Clinical use of aztreonam in a psychogeriatric population. Acta Clin Belg 1992;47:251-255.
- Andrews R, Fasoli R, Scoggins WG, et al. Combined aztreonam and gentamicin therapy for pseudomonal lower respiratory tract infections. Clin Therap 1994;16:236-252.
AZACTAM and the Bristol-Myers
Squibb logo are registered trademarks of Bristol-Myers Squibb Company. All other trademarks are the property of their respective owners.
|